Literature DB >> 24699677

Widespread hypermetabolism in symptomatic and asymptomatic episodes in Kleine-Levin syndrome.

Yves Dauvilliers1, Sophie Bayard1, Régis Lopez1, Frederic Comte2, Michel Zanca2, Philippe Peigneux3.   

Abstract

BACKGROUND: No reliable biomarkers are identified in KLS. However, few functional neuroimaging studies suggested hypoactivity in thalamic and hypothalamic regions during symptomatic episodes. Here, we investigated relative changes in regional brain metabolism in Kleine-Levin syndrome (KLS) during symptomatic episodes and asymptomatic periods, as compared to healthy controls.
METHODS: Four drug-free male patients with typical KLS and 15 healthy controls were included. 18-F-fluorodeoxy glucose positron emission tomography (PET) was obtained in baseline condition in all participants, and during symptomatic episodes in KLS patients. All participants were asked to remain fully awake during the whole PET procedure.
RESULTS: Between state-comparisons in KLS disclosed higher metabolism in paracentral, precentral, and postcentral areas, supplementary motor area, medial frontal gyrus, thalamus and putamen during symptomatic episodes, and decreased metabolism in occipital and temporal gyri. As compared to healthy control subjects, KLS patients in the asymptomatic phase consistently exhibited significant hypermetabolism in a wide cortical network including frontal and temporal cortices, posterior cingulate and precuneus, with no detected hypometabolism. In symptomatic KLS episodes, hypermetabolism was additionally found in orbital frontal and supplementary motor areas, insula and inferior parietal areas, and right caudate nucleus, and hypometabolism in the middle occipital gyrus and inferior parietal areas.
CONCLUSION: Our results demonstrated significant hypermetabolism and few hypometabolism in specific but widespread brain regions in drug-free KLS patients at baseline and during symptomatic episodes, highlighting the behavioral state-dependent nature of changes in regional brain activity in KLS.

Entities:  

Mesh:

Year:  2014        PMID: 24699677      PMCID: PMC3974864          DOI: 10.1371/journal.pone.0093813

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Kleine-Levin syndrome (KLS) is an extremely rare disease characterized by recurrent episodes of hypersomnia associated with at least one of the following symptoms: cognitive abnormalities, behavioral disturbances, hyperphagia or hypersexuality [1]–[3]. Nowadays diagnostic criteria for KLS are only clinically defined [3]. No reliable biomarker has been identified yet, and the underlying pathophysiology of KLS remains unknown. So far, four post-mortem brain examinations have been reported with inconsistent results [4], [5]. However, inflammatory encephalitis within thalamic and hypothalamic regions was found in two patients. Results of the few functional neuroimaging studies conducted in KLS during and between symptomatic episodes are also conflicting regarding changes in brain activity, particularly in thalamic, hypothalamic, basal ganglia structures and in fronto-temporal areas [6]–[12]. Inconsistencies may stem from the use of different imaging methods (single photon emission tomography [SPECT], 18F-fluorodeoxyglucose positron emission tomography [18F-FDG-PET]), small sample size, imaging at different stages of disease evolution and delay from episode onset, various phenotypes during imaging recording, and medication intake. Moreover, to the best of our knowledge no PET-scan imaging studies compared patients with KLS to healthy controls. In the present study, brain regional metabolism was investigated using 18F-FDG-PET scan in 4 typical boys with KLS during both symptomatic and asymptomatic states, and data were compared to 15 healthy controls.

Methods

Participants

All subjects and both parents on behalf of the minors enrolled in the study gave their written informed consent to participate in, study being approved by the Montpellier University Hospital’s ethics committee. Four male patients were diagnosed with typical KLS [3], with onset of symptoms at 15–16 years, 2 to 10 episodes of hypersomnia and derealisation/behavioral disturbances since the beginning with a duration ranging from 4 to 10 days (Table 1). Two patients presented disinhibition, hypersexuality and increased food intake without megaphagia. All patients experienced derealization during symptomatic episodes. Each patient was hospitalized twice for 2 days during symptomatic and asymptomatic episodes to record sleep, performed clinical and neuropsychological examns and underwent 18F-FDG-PET scanning at rest (Table 1).
Table 1

Demographic, clinical and neuropsychological characteristics of 4 patients with Kleine-Levin Syndrome.

Patient 1Patient 2Patient 3Patient 4
Demographical data
Age, years16161716
Onset, years15151615
Body mass index, kg/m222.424.220.523
Clinical data
Time elapsed since the first attack, month1611913
Number of attacks since disease onset10852
Duration of a single attack, days5 to 75 to 74 to 510
First attack precipitating factorInfectionAlcohol intakeSleep deprivationInfection
Questionnaires
Epworth Sleepiness Scale score* 17_516_515_416_3
Fatigue severity scale* 9_28_16_09_0
Sleep abnormalities
Hypersomnia++++
Sleep inertia++++
Postepisode transient insomnia
Intense dreaming
Hypnagogic hallucinations
Sleep paralysis
Sexual disinhibition
Disinhibition, hypersexuality++
Increased masturbation++
Eating behaviour
Compulsive eating
Increased food intake++
Decreased of appetite++
Altered perception
Erroneous perception+
Derealization++++
Psychological changes
Irritability+++
Depressed mood
Agitation
Less polite++
Anxiety
Compulsions
PET-scan
in asymptomatic episodeone month after 9thone month after 7thone month after 5th3 months after 2nd
in symptomatic episode10th attack, day 38th attack, Day 25th attack, Day 22nd attack, Day 3

* = during last attack_ in between attack; − = Absent;+ = Present.

* = during last attack_ in between attack; − = Absent;+ = Present. All participants were drug-free at the time of evaluation; none was previously treated for KLS. Follow-up and clinical re-evaluations of these patients confirmed the accuracy of KLS diagnosis without any associated psychiatric comorbidities, without any residual symptoms in between symptomatic episodes, and suggested disease recovery in patients 1 and 3. Fifteen healthy controls (12 males, mean age 28±14.9, range 10–51 years) participated in the study that included 10 young subjects with a mean age 17.9 years. Healthy controls were identified with normal PET scans, All controls had normal neurological exams, normal and regular sleep, were free of any treatment that may interfere with sleep, motor or psychological functions, None of the controls suffered from major depression or any psychiatric disorder as assessed by clinical interview.

PET Procedure

During symptomatic episodes, PET scans were all performed Day 2 to Day 3 after episode onset as detailed in table 1. PET scans in asymptomatic periods were obtained one to three months after the last day of the previous symptomatic episode (Table 1). All participants received via intravenous line an injection of 5.5 MBq/kg of FDG, in a quiet room between 10∶00 a.m. and 1∶00 p.m., with eyes closed to avoid noxious, auditory or visual stimuli. Before the injection and up to PET scan acquisition, all participants were asked ‘to resist sleeping’ in order to remain fully awake during the procedure, but also not to move and not to talk. The vigilance state of patients and controls was supervised clinically and by video by both a neurologist (YD) and a technician during the whole process. None of the subjects slept during the PET scan acquisition. PET images were acquired during 15 min using a Biograph Emission Duo LSO (Siemens Corp) camera 30 minutes after FDG injection. The volume was reconstructed using a FORE rebinning algorithm followed by an OSEM reconstruction with 16 subsets and eight iterations, following the manufacturer’s operating instructions. The resulting images contained 47 contiguous slices with a plane separation of 5 mm.

Data Analysis

Metabolic data were analysed using SPM8 software (Wellcome Department of Cognitive Neurology, Institute of Neurology, London, UK) implemented in MATLAB (Mathworks, Sherborn, MA). Images were spatially normalized into the ICBM standard space using 2nd degree B-spline interpolations, then smoothed using a 16-mm full-width half-maximum isotropic Gaussian kernel. Areas of significant relative (instead of absolute) change between conditions of interest were estimated according to the general linear model using linear contrasts. Global metabolism adjustment was performed using proportional scaling. Age was entered in the analysis as a confounding variable. Main contrasts estimated the main effect of pathology [controls vs. KLS at baseline, controls vs. KLS in acute episode] to identify the brain regions where glucose metabolism was decreased (or increased) in the KLS as compared to controls. In a second step, the condition effects were assessed within the KLS population [baseline vs. acute episode] to identify brain areas where glucose metabolism was decreased (or increased) as a function of the presence of acute symptoms in KLS. The resulting set of voxel values for each contrast constituted a map of the T statistics [SPM{T}], thresholded at p ≤.001 (T≥3.35), uncorrected (comparisons with controls) or p ≤.05 (T≥1.71), uncorrected (direct comparison between acute and baseline state in KLS). Minimal spatial extent of reported brain areas is 50 contiguous significant voxels.

Results

Comparison of Cerebral Glucose Metabolism between Symptomatic and Asymptomatic Episodes in KLS

A direct comparison between states in KLS patients showed a higher relative metabolism during the symptomatic episodes in paracentral, precentral, and postcentral areas, supplementary motor area, superior medial frontal gyrus and in the left thalamus and putamen (lentiform nucleus) bilaterally (Table 2, Fig. 1). Noticeably, a statistical trend for hypermetabolism was similarly found within the thalamus and putamen during symptomatic KLS episodes compared to healthy controls, without any changes within these areas between KLS at baseline and controls. Conversely, relative lower metabolism was found during symptomatic KLS episodes bilaterally in occipital gyri, in left lingual gyrus and right angular and middle and superior temporal gyri (Table 2, Fig. 1).
Table 2

Statistical parametric mapping results of brain regions showing relative metabolism changes during symptomatic episodes and asymptomatic periods in Kleine-Levin Syndrome KLS (n = 4).

HemisphereCoordinates
A. Episodes vs. Baseline(L)eft/(R)ightxyzZ-score
Precentral gyrusL−16−24563.23
Postcenral gyrusR16−38642.74
Supplementary motor areaR14−4542.27
Postcenral gyrusL−64−14262.76
Paracentral lobuleR8−14441.86
Superior Medial Gyrus068282.21
ThalamusL−18−2661.78
Putamen (lentiform nucl.)R28−18141.87
Putamen (lentiform nucl.)L−32−1261.78
b. Baseline vs Episodes (L)eft/(R)ight x y z Z-score
Inferior Occipital GyrusR28−94−23.29
Lingual GyrusL−28−96−162.79
Middle Occipital GyrusL−24−9222.82
Angular GyrusR38−74322.29
Middle Temporal GyrusR68−30−102.78
Superior Temporal GyrusR62−54142.37

Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.05, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed.

Figure 1

Regional cerebral increases (yellow blobs) and decreases (blue blobs) in Kleine-Levin patients (n = 4) during symptomatic episodes as compared to baseline asymptomatic period, superimposed on a template T1-weighted MRI.

Activations are displayed at p<.05, uncorrected, for clusters >50 voxels.

Regional cerebral increases (yellow blobs) and decreases (blue blobs) in Kleine-Levin patients (n = 4) during symptomatic episodes as compared to baseline asymptomatic period, superimposed on a template T1-weighted MRI.

Activations are displayed at p<.05, uncorrected, for clusters >50 voxels. Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.05, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed. Inspection of individual data showed that increased (respectively decreased) regional glucose consumption was consistent across the 4 KLS patients who exhibited similar differential patterns.

Regional Cerebral Glucose Metabolism in KLS at Baseline Compared to Healthy Controls

A relative increased brain regional metabolism was found in KLS patients at baseline (i.e. in asymptomatic periods) compared to healthy controls in the medial, middle and inferior frontal cortices, inferior and middle temporal gyri, left posterior cingulate, and the right precuneus (Table 3; Fig. 2). Conversely, no hypometabolism was found.
Table 3

Statistical parametric mapping results of brain regions showing relative metabolism changes in patients with Kleine-Levin Syndrome KLS (n = 4, baseline) compared to healthy controls (n = 15).

HemisphereCoordinates
Hypermetabolism in KLS(L)eft/(R)ightxyzZ-score
Medial Frontal GyrusL−660−164.47
Medial Frontal GyrusR1264124.46
Inferior frontal gyrusR484243.67
Middle frontal gyrusR3640123.63
Middle frontal gyrusR6030283.63
Inferior Temporal GyrusR52−28−224.17
Middle Temporal GyrusR66−24−124.26
Superior Temporal GyrusR54623.46
PrecuneusR24−54224.07
Posterior cingulateL−18−56183.49

Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.001, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed.

Figure 2

Regional cerebral increases in Kleine-Levin patients as compared to controls during symptomatic episodes (yellow) and asymptomatic period (red), superimposed on a template T1-weighted MRI.

Activations are displayed at p<.001, uncorrected, for clusters >50 voxels.

Regional cerebral increases in Kleine-Levin patients as compared to controls during symptomatic episodes (yellow) and asymptomatic period (red), superimposed on a template T1-weighted MRI.

Activations are displayed at p<.001, uncorrected, for clusters >50 voxels. Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.001, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed.

Regional Cerebral Glucose Metabolism during KLS Episodes Compared to Healthy Controls

A relative increased brain metabolism was found during symptomatic episodes in KLS patients as compared to healthy controls in inferior, superior medial and orbital frontal areas, supplementary motor area, left lingual and right inferior and superior temporal gyri, precuneus, precentral and posterior regions, left insula and inferior parietal areas, and right caudate nucleus in the striatum. Hypometabolism was found in the middle occipital gyrus bilaterally, in right inferior parietal areas and in the left cuneus (Table 4, Fig. 2).
Table 4

Statistical parametric mapping results of brain regions showing relative metabolism changes during symptomatic episodes in patients with Kleine-Levin Syndrome KLS (n = 4, acute episode) compared to healthy controls (n = 15).

HemisphereCoordinates
a. Hypermetabolism in KLS(L)eft/(R)ightxyzZ-score
Inferior frontal gyrusL−4212223.54
Superior Medial FrontalR1264125.13
Superior Orbital FrontalL−1818−163.58
Supplementary motor areaR120544.62
Left InsulaL−38−243.93
Right Caudate NucleusR1214−123 47
Inferior Temporal GyrusR50−26−224.25
Superior Temporal GyrusR54423.79
Inferior Parietal LobuleL−48−54383.76
Postcentral GyrusL−54−2423.52
Precentral GyrusL−42−8403.61
Precentral GyrusL−602343.47
PrecuneusR22−52224.29
PrecuneusL−16−54163.96
Lingual gyrusL−18−42−23.28
b. Hypometabolism in KLS
Middle Occipital GyrusR28−9684.40
Middle Occipital GyrusL−22−100123.61
Angular GyrusR38−74324.02
Inferior Parietal GyrusR66−44243.63
CuneusL−14−104−43.51

Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.001, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed.

Note. Coordinates x, y, z refer to the standard Talairach and Tournoux33 stereotactic space. Activation peaks’ significance is reported at the voxel-level, thresholded at p ≤.001, with a cluster extent >50 voxels. Only the most representative voxels in each anatomical structure are displayed. To minimize the confounding factor of age, similar analyses were conducted comparing FDG-PET patterns with young control participants (n = 10; mean age 17.9 years). These analyses disclosed similar results although effects were less pronounced in cortical areas, especially in frontal cortices, which is likely due to the loss of statistical power.

Discussion

We report here the results of a case-control 18F-FDG-PET scan study in KLS during and between episodes. Between states comparison within KLS consistently revealed higher metabolism during symptomatic episodes in paracentral, precentral, postcentral and supplementary motor areas, frontal gyrus, thalamus and putamen, and hypometabolism in the occipital and temporal gyri. We also demonstrated significant. hypermetabolism and few hypometabolism in specific but widespread cortical network in drug-free fully awake KLS patients at baseline and during symptomatic episodes compared to healthy controls. Our results may contrast from previous SPECT studies having suggested hypoperfusion particularly within the thalamus but also in the temporal and frontal lobes and basal ganglia during symptomatic episodes [6]–[10]. However, no control group was included and no statistical parametric mapping analysis of SPECT images was available. A KLS case report using FDG PET-scan showed decreased metabolism in the hypothalamus, caudate nuclei and striatum during symptomatic as compared to asymptomatic phases but the quantitative method was a simple subtraction without statistical evaluation of the observed differences [11]. More recently, a PET-scan study conducted on two KLS cases reported more complex regional metabolism modifications with decreased glucose consumption in the hypothalamus, frontal areas and posterior regions but also increased activity in anterior caudate, cingulate and the premotor cortex during symptomatic episodes [12]. Discrepancies and variability in metabolic patterns between KLS studies [4], [5] and with our results may stem from various factors including the image scanning method (e.g. SPECT vs. PET), the type of analysis (mere subtraction, statistics in the general linear model), time of imaging after the onset of the symptomatic episodes (i.e. here, PET scans were all performed Day 2 to Day 3 after episode onset), participants’ age and disease evolution, medication intake (i.e. lithium) [12], the limited number of patients included, and in particular the variable phenotype during actual imaging recording (awake vs. sleepy, presence of derealization, hypersexuality, hyperphagia…). The latter issue is of major concern since disease symptoms are not stable between episodes for a single patient, nor between patients [1], [2], [4], [13]. Post-mortem brain examination also revealed large between-patient differences regarding the presence of inflammation and lesion localizations [4], [5]. However, inspection of individual images disclosed consistent pattern of metabolism changes in the main areas across our four participants, a consistency potentially related to an homogeneous age group being awake and drug-free at the time of scanning. We reported here a systematic and controlled comparison between KLS at baseline and during symptomatic episodes and healthy controls. Although most of literature findings suggested potential temporal, frontal and basal ganglia hypoperfusions persisting during asymptomatic periods after many recurrences and years of disease duration, these conclusions are hampered by a lack of comparisons with healthy controls [2], [4], [5], [6]–[12]. Our results disclose restricted regional hypometabolism during symptomatic episodes, and none in the asymptomatic periods even though our patients were young, with recent disease onset and in disease regression for two of them. In contrast, we found increased brain metabolism in a specific but widespread set of brain regions in KLS in asymptomatic periods but especially during symptomatic episodes compared to controls even in the subanalysis including the young control participants only. Regional hypometabolism in occipital, lingual and temporal gyri during symptomatic episodes may play a role in the pathophysiology of delusions, derealization, and disinhibition [4], [5], [13]. Conversely, hypermetabolism within the supplementary motor area, frontal gyri, thalamus and putamen may explain some behavioral symptoms, may reflect a compensatory activity for hypoactivated adjacent brain areas [4], [5], [13], but may also reflect the vigilance state during symptomatic episodes. Indeed, sleep-deprivation studies in normal controls have reported that poor performance elicit an attentional recovery that may manifests as greater activation in the prefrontal cortex, parietal lobe and cingulate regions [14]. This observation might be related to the increased activation patterns found in KLS patients during a working memory task, reflecting higher efforts than controls [15]. We previously reported hypermetabolism in drug-free patients with narcolepsy-cataplexy in fully awake condition in the cingulated cortex, cuneus and lingual gyrus compared to controls [16]. Thus, we suggest that the vigilance level during the scanning procedure is a critical issue in central hypersomnias. Investigation of brain functional imaging in patients with central hypersomnia should be performed in well-defined vigilance state, i.e. in wakefulness state to avoid results showing altered functional neurocircuitry secondary to sleepiness. None of our subjects slept during the scanning acquisition as controlled clinically and by video; however unfortunately the vigilance state was not monitored through EEG recording during the PET procedure. In conclusion, we demonstrated significant hypermetabolism and few hypometabolism in specific but widespread brain regions in drug-free fully awake KLS patients at baseline and during symptomatic episodes compared to healthy controls, highlighting the behavioral state-dependent nature of global cortical function. Further studies are needed in larger populations to elucidate the functional activation/inhibition of brain regions involved in particular symptoms of KLS patients.
  15 in total

1.  Increased cerebral response during a divided attention task following sleep deprivation.

Authors:  S P Drummond; J C Gillin; G G Brown
Journal:  J Sleep Res       Date:  2001-06       Impact factor: 3.981

2.  [Kleine-Levin syndrome: contribution of brain SPECT in diagnosis].

Authors:  M Arias; J M Crespo Iglesias; J Pérez; I Requena- Caballero; A Sesar-Ignacio; M Peleteiro-Fernández
Journal:  Rev Neurol       Date:  2002 Sep 16-30       Impact factor: 0.870

Review 3.  Recurrent hypersomnia: a review of 339 cases.

Authors:  Michel Billiard; Isabelle Jaussent; Yves Dauvilliers; Alain Besset
Journal:  Sleep Med Rev       Date:  2010-10-20       Impact factor: 11.609

4.  Episodic diencephalic hypoperfusion in Kleine-Levin syndrome.

Authors:  Seung Bong Hong; Eun Yeon Joo; Woo Suk Tae; Jaewoo Lee; Sun Jung Han; Hyang Woon Lee
Journal:  Sleep       Date:  2006-08       Impact factor: 5.849

5.  SPECT findings in the Kleine-Levin syndrome.

Authors:  Yu-Shu Huang; Christian Guilleminault; Pan-Fu Kao; Feng-Yuan Liu
Journal:  Sleep       Date:  2005-08-01       Impact factor: 5.849

6.  Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses.

Authors:  Y Dauvilliers; G Mayer; M Lecendreux; E Neidhart; R Peraita-Adrados; K Sonka; M Billiard; M Tafti
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

7.  Relationship between Kleine-Levin syndrome and upper respiratory infection in Taiwan.

Authors:  Yu-Shu Huang; Christian Guilleminault; Kuang-Lin Lin; Fang-Ming Hwang; Feng-Yuan Liu; Yen-Ping Kung
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

Review 8.  Kleine-Levin syndrome: a systematic review of 186 cases in the literature.

Authors:  I Arnulf; J M Zeitzer; J File; N Farber; E Mignot
Journal:  Brain       Date:  2005-10-17       Impact factor: 13.501

9.  A brain PET study in patients with narcolepsy-cataplexy.

Authors:  Yves Dauvilliers; Frederic Comte; Sophie Bayard; Bertrand Carlander; Michel Zanca; Jacques Touchon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10-22       Impact factor: 10.154

10.  Kleine-Levin syndrome: a systematic study of 108 patients.

Authors:  Isabelle Arnulf; Ling Lin; Nathan Gadoth; Jennifer File; Michel Lecendreux; Patricia Franco; Jamie Zeitzer; Betty Lo; Juliette H Faraco; Emmanuel Mignot
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

View more
  13 in total

Review 1.  Clinical update on central hypersomnias.

Authors:  Laura Pérez-Carbonell; Guy Leschziner
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

2.  Cerebrospinal Fluid Orexin A Levels and Autonomic Function in Kleine-Levin Syndrome.

Authors:  Jing Yu Wang; Fang Han; Song X Dong; Jing Li; Pei An; Xiao Zhe Zhang; Yuan Chang; Long Zhao; Xue Li Zhang; Ya Nan Liu; Han Yan; Qing Hua Li; Yan Hu; Chang Jun Lv; Zhan Cheng Gao; Kingman P Strohl
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

Review 3.  The Development of Sleep Medicine: A Historical Sketch.

Authors:  Hartmut Schulz; Piero Salzarulo
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

4.  Prevalence and Mimics of Kleine-Levin Syndrome: A Survey in French-Speaking Switzerland.

Authors:  Oussama Habra; Raphaël Heinzer; Jose Haba-Rubio; Andrea O Rossetti
Journal:  J Clin Sleep Med       Date:  2016-08-15       Impact factor: 4.062

5.  Recurrent hypersomnia: Report of medication-responsive cases.

Authors:  Bruna V Perin; Iorrana Rodrigues; Franciele T B Giasson; Matheus Balen; Naiana Posenato; Cassiano M Forcelini
Journal:  Sleep Sci       Date:  2015-06-29

6.  [18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia.

Authors:  Yves Dauvilliers; Elisa Evangelista; Delphine de Verbizier; Lucie Barateau; Philippe Peigneux
Journal:  Front Neurol       Date:  2017-07-20       Impact factor: 4.003

Review 7.  Kleine-Levin syndrome: clues to aetiology.

Authors:  Saad Mohammed AlShareef; Richard Mark Smith; Ahmed Salem BaHammam
Journal:  Sleep Breath       Date:  2018-03-12       Impact factor: 2.816

8.  Regional brain metabolism differs between narcolepsy type 1 and idiopathic hypersomnia.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Bruce Crosson; Carolyn C Meltzer; David B Rye; Jonathon A Nye
Journal:  Sleep       Date:  2021-08-13       Impact factor: 5.849

Review 9.  Functional magnetic resonance imaging in narcolepsy and the kleine-levin syndrome.

Authors:  Maria Engström; Tove Hallböök; Attila Szakacs; Thomas Karlsson; Anne-Marie Landtblom
Journal:  Front Neurol       Date:  2014-06-25       Impact factor: 4.003

10.  Functional brain imaging using 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in 138 patients with Kleine-Levin syndrome: an early marker?

Authors:  Benjamin Dudoignon; Laure-Eugénie Tainturier; Pauline Dodet; Géraldine Bera; Elisabeth Groos; Charlotte Chaumereuil; Jean-Baptiste Maranci; Aurélie Kas; Isabelle Arnulf
Journal:  Brain Commun       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.